Hematology (all articles)
Perioperative guidelines on antiplatelet and anticoagulant agents: 2022 Update.
21 Jan, 2022 | 09:53h | UTC
RCT: In patients with previously untreated Diffuse Large B-Cell Lymphoma, a modified regimen of R-CHOP (pola-R-CHP), in which vincristine was replaced with polatuzumab, was associated with improved outcomes compared to standard R-CHOP treatment.
21 Jan, 2022 | 09:28h | UTCPolatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
Expert consensus for plasma and platelet transfusion practice in critically ill children.
20 Jan, 2022 | 08:44h | UTC
RCT: In non–critically ill hospitalized patients with COVID-19, the use of a P2Y12 Inhibitor (ticagrelor in 63% of patients and clopidogrel in 37%) in addition to a therapeutic dose of heparin did not improve survival free of organ support compared to therapeutic heparin alone.
19 Jan, 2022 | 08:56h | UTCEditorial: Antiplatelet Therapy in Patients With COVID-19—More Is Less? – JAMA
Commentary: Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19 – HealthDay
A single-arm study evaluated Naive T-Cell depleted peripheral blood stem-cell grafts for the prevention of chronic graft-versus-host disease.
19 Jan, 2022 | 08:22h | UTCNaive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease – Journal of Clinical Oncology
Commentary: New graft strategy may improve outcomes for blood stem cell recipients – University of Pittsburg
Prolonged follow-up of RCT: Emission Tomography–driven strategy in advanced Hodgkin Lymphoma.
19 Jan, 2022 | 08:16h | UTCPositron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study – Journal of Clinical Oncology (link to abstract – $ for full-text)
Case series of Thrombosis with Thrombocytopenia Syndrome after Covid-19 vaccination in the US.
18 Jan, 2022 | 09:41h | UTC
RCT: Sirolimus plus prednisolone vs. sirolimus monotherapy for kaposiform hemangioendothelioma.
18 Jan, 2022 | 09:08h | UTCSirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial – Blood (link to abstract – $ for full-text)
Systematic Review: Restrictive transfusion thresholds can safely decrease transfusions by 41% across a broad range of clinical contexts.
14 Jan, 2022 | 08:18h | UTCTransfusion thresholds for guiding red blood cell transfusion – Cochrane Library
Related:
Research: Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery
Transfusion Requirements After Cardiac Surgery: The TRACS Randomized Controlled Trial – JAMA
Commentary on Twitter
https://twitter.com/cochraneINJ/status/1473667822542888964
The COVID-19 Treatment Guidelines Panel’s Statement on Anticoagulation in Hospitalized Patients With COVID-19 – in the absence of contraindications, use therapeutic-dose anticoagulation with low molecular weight heparin for hospitalized patients not in the ICU who have a D-dimer above the upper limit of normal.
12 Jan, 2022 | 09:11h | UTC
RCT: Among patients younger than 21 years of age with provoked thromboembolism, anticoagulation for 6 weeks was non-inferior vs. 12 weeks on the risk of recurrence and bleeding events.
12 Jan, 2022 | 08:53h | UTCEffect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Duration of Anticoagulant Treatment for Acute Provoked Venous Thromboembolism in Pediatric Patients – JAMA (free for a limited period)
RCT: Eltrombopag added to immunosuppression is associated with improved hematologic response vs. immunosuppression alone in previously untreated patients with severe aplastic anemia.
12 Jan, 2022 | 08:46h | UTCEltrombopag Added to Immunosuppression in Severe Aplastic Anemia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
A randomized trial comparing immunosuppression (horse ATG and cyclosporine) with the same therapy plus eltrombopag showed more rapid and complete responses with the addition of eltrombopag. https://t.co/nH7rkeCMAS pic.twitter.com/i8iTIq8FSG
— NEJM (@NEJM) January 5, 2022
RCT: Interferon-alpha vs. Hydroxyurea in Polycythemia Vera and Essential Thrombocythemia.
12 Jan, 2022 | 08:35h | UTC
Review: Management of coagulopathy in bleeding patients.
12 Jan, 2022 | 08:34h | UTCManagement of Coagulopathy in Bleeding Patients – Journal of Clinical Medicine
Best Practice Recommendations: Management of adults and children receiving CAR T-cell therapy.
12 Jan, 2022 | 08:31h | UTC
RCT: In children with sickle cell anemia, hydroxyurea in moderate doses (20 mg/kg per day) is not better than low doses (10 mg/kg per day) for primary stroke prevention.
11 Jan, 2022 | 02:10h | UTCHydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial – The Lancet Haematology (link to abstract – $ for full-text)
[Preprint] RCT: In symptomatic adults above 18 years positive for SARS-CoV-2, early outpatient treatment with high-titer convalescent plasma significantly reduced hospitalizations.
8 Jan, 2022 | 23:28h | UTCNews release: Early Use of Convalescent Plasma May Help Outpatients with COVID-19 Avoid Hospitalization – Johns Hopkins Medicine
Commentary: Convalescent plasma shows renewed promise for COVID-19 in outpatient trial – Science
In a large retrospective cohort study of patients with atrial fibrillation 65 years or older, treatment with rivaroxaban compared with apixaban was associated with increased risk of major ischemic or hemorrhagic events.
8 Jan, 2022 | 22:37h | UTCCommentary: Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study – TCTMD
Related:
Retrospective cohort study: In patients with venous thromboembolism (VTE), treatment with apixaban was associated with lower rates for recurrent VTE and bleeding compared to rivaroxaban.
8 Jan, 2022 | 22:36h | UTCCommentaries:
Apixaban shows superior effectiveness, safety compared to rivaroxaban – ACP Internist
Recurrent VTE and Bleeding With Apixaban vs. Rivaroxaban – American College of Cardiology
RCT: Among patients hospitalized with COVID-19 at increased risk for venous thromboembolism, post-discharge thromboprophylaxis with Rivaroxaban for 35 days may improve outcomes.
17 Dec, 2021 | 09:50h | UTCInvited commentary: Anticoagulation in COVID-19 – The Lancet
Commentary on Twitter
NEW: The role of extended thromboprophylaxis in patients hospitalised with COVID-19 at risk for thrombotic events after discharge – findings from MICHELLE trial https://t.co/OWcmjCLBTw pic.twitter.com/3Bl4lV16Va
— The Lancet (@TheLancet) December 16, 2021
How to recognize and manage COVID-19-associated coagulopathy.
13 Dec, 2021 | 09:45h | UTCHow to recognize and manage COVID-19-associated coagulopathy – Hematology, ASH Education Program
COVID-19 and thrombosis: searching for evidence.
13 Dec, 2021 | 09:47h | UTCCOVID-19 and thrombosis: searching for evidence – Hematology, ASH Education Program
Hematology, the ASH Education Program – series of review articles with clinical cases published annually by the American Society of Hematology.
13 Dec, 2021 | 08:45h | UTCHomepage: Hematology, the ASH Education Program
Non-inferiority randomized trial showed radiotherapy can be safely omitted in many children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma.
10 Dec, 2021 | 10:04h | UTC
Update in the diagnosis and management of acute pulmonary embolism for the non-respiratory physician.
9 Dec, 2021 | 10:00h | UTC